Company intelligence / Profile preview
Agentix
Dana Point, California, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Agentix has advanced its lead asset, AGTX-2004, to an IND-cleared Phase 1 clinical trial in obesity and metabolic disease. AGTX-2003 has shown preclinical efficacy reducing liver steatosis and gene expression linked to NASH. The company targets a suite of metabolic, inflammatory, and CNS disorders via novel small molecules acting on the endocannabinoid system[1][2][8].
- Therapeutic areas
- EndocrinologyGastroenterologyPulmonologyDermatologyCardiovascularOncologyNeurology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
National Health Research Institute (Taiwan)Research Triangle Institute International
Beyond the preview
Go deeper on Agentix.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Agentix.